Cytek Biosciences Announces Pricing of Its Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Cytek Biosciences (CTKB) IPO Opens 24% Higher
July 23, 2021 12:10 PM EDTToday's IPO for Cytek Biosciences, Inc. (Nasdaq: CTKB) opened for trading at $21.10 after pricing 6,749,330 shares of its common stock at a price to the public of $17.00 per share.
Morgan Stanley, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cowen are acting as joint book running managers... More
